AVE REVENUES DOUBLE IN SECOND QUARTER TO $38 MIL. AS FIRM LOGS $3 MIL. IN U.S. STENT SALES FOLLOWING DEC. 23 APPROVAL; J&J FOURTH QUARTER SALES UP 2.3%
This article was originally published in The Gray Sheet
Executive Summary
Arterial Vascular Engineering's $2.9 mil. in initial U.S. sales of the Micro Stent II coronary stent just one week after FDA approval Dec. 23, coupled with strong international stent volume, was the driving force behind a 110% jump in corporate revenues to $38.3 mil. for the second quarter ended Dec. 31.